A multi-model study to inform the United States' 2035 NDC.

In 2025, countries are expected to submit a third round of nationally determined contributions (NDCs) that outline emission reduction goals for 2035. These new NDCs will be important for global alignment with the Paris Agreement's long-term goals. Setting an ambitious and plausible 2035 NDC in the United States (US) could be crucial in motivating high levels of ambition globally.

Computed Tomographic Findings in Lemmel Syndrome: A Rare Cause of Obstructive Jaundice.

Introduction: Obstructive jaundice resulting from a duodenal diverticulum is known as Lemmel syndrome. Lemmel syndrome should be included in the differential diagnosis in patients presenting with obstructive jaundice in the absence of choledocholithiasis, mass, or a stricture.

Aims And Objectives: To describe the computed tomography (CT) findings in patients with Lemmel syndrome.

Targeting Yes-Associated Protein (YAP) in Breast Cancer: In Silico Molecular Dynamics, Luminescence-Based In Vitro, and In Vivo Validation of Rauvolfia tetraphylla-Derived Inhibitors.

The study aims to elucidate the pharmacological mechanism of Rauvolfia tetraphylla against breast cancer through a comprehensive, multi-faceted approach. This includes molecular docking, molecular dynamics, and experimental validation. Initial screening via ADME analysis and network pharmacology identified key compounds and potential targets.

Gemcitabine Cisplatin and Durvalumab Experience in Advanced Biliary Tract Cancers: A Real-World, Multicentric Data From India.

Purpose: Biliary tract cancers (BTCs) are usually diagnosed in advanced stages, where treatment options are either palliative chemotherapy and/or best supportive care. The breakthrough results of the TOPAZ-1 trial demonstrated a 24% decrease in risk of death at 2 years with the addition of durvalumab to chemotherapy.

Materials And Methods: This was a multicenter retrospective cohort study conducted across 14 institutions in India.

Safety assessment of the world's first novel cocktail of two monoclonal antibodies in WHO category-III animal-bite patients.

Background: Rabies, a zoonotic disease, poses a significant global public health challenge, and post-exposure prophylaxis (PEP) is crucial for prevention. Monoclonal antibodies (mAbs) have emerged as a promising alternative to rabies immunoglobulins due to their high efficacy and standardized manufacturing process.

Materials And Methods: A prospective, open-label post-marketing surveillance study was conducted with patients of WHO category-III suspected rabid animal bites.